B细胞激活因子及其靶向药物与炎症性肠病的研究进展

李琳; 刘海燕; 王立俊

doi:10.7499/j.issn.1008-8830.2309126

PDF(540 KB)

HTML

中国当代儿科杂志 ›› 2024, Vol. 26 ›› Issue (3) : 315-320. DOI: 10.7499/j.issn.1008-8830.2309126

综述

B细胞激活因子及其靶向药物与炎症性肠病的研究进展

李琳, 刘海燕, 王立俊

作者信息 +

Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease

LI Lin, LIU Hai-Yan, WANG Li-Jun

Author information +

文章历史 +

摘要

B细胞激活因子（B-cell activating factor, BAFF）作为B细胞的关键调节因子，参与多种自身免疫性疾病。炎症性肠病（inflammatory bowel disease, IBD）是一组病因尚不明确的慢性、反复发作的肠道炎症性疾病，近年来全球发病率呈上升趋势。多种因素引起的异常免疫反应与IBD发病密切相关，B细胞异常活化及自身抗体产生增加在溃疡性结肠炎的发病中已得到证实，而BAFF是否参与IBD发病机制尚不明确。该文就目前关于BAFF在IBD发病机制中的潜在作用以及在IBD中针对BAFF的靶向治疗研究进行综述，旨在为IBD靶向治疗提供思路。

Abstract

B-cell activating factor (BAFF), a critical regulator of B cells, is involved in various autoimmune diseases. Inflammatory bowel disease (IBD) is a group of chronic and recurrent intestinal inflammatory disorders with unclear etiology, and its global incidence has been increasing in recent years. Abnormal immune responses triggered by multiple factors are closely related to the pathogenesis of IBD. Previous studies have confirmed the association of B-cell abnormal activation and increased production of autoantibodies with the development of ulcerative colitis. However, the involvement of BAFF in the mechanisms of IBD remains unclear. This review summarizes the potential role of BAFF in the pathogenesis of IBD and provides an overview of targeted therapies on BAFF in IBD, aiming to contribute insights for targeted treatments of IBD.

导出引用

李琳, 刘海燕, 王立俊. B细胞激活因子及其靶向药物与炎症性肠病的研究进展[J]. 中国当代儿科杂志. 2024, 26(3): 315-320 https://doi.org/10.7499/j.issn.1008-8830.2309126

LI Lin, LIU Hai-Yan, WANG Li-Jun. Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(3): 315-320 https://doi.org/10.7499/j.issn.1008-8830.2309126

参考文献

1 Lee M, Chang EB. Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues[J]. Gastroenterology, 2021, 160(2): 524-537. PMID: 33253681. PMCID: PMC8098834. DOI: 10.1053/j.gastro.2020.09.056.
2 Brni? D, Martinovic D, Zivkovic PM, et al. Serum adropin levels are reduced in patients with inflammatory bowel diseases[J]. Sci Rep, 2020, 10(1): 9264. PMID: 32518265. PMCID: PMC7283308. DOI: 10.1038/s41598-020-66254-9.
3 Neurath MF. Cytokines in inflammatory bowel disease[J]. Nat Rev Immunol, 2014, 14(5): 329-342. PMID: 24751956. DOI: 10.1038/nri3661.
4 Clough JN, Omer OS, Tasker S, et al. Regulatory T-cell therapy in Crohn's disease: challenges and advances[J]. Gut, 2020, 69(5): 942-952. PMID: 31980447. PMCID: PMC7229901. DOI: 10.1136/gutjnl-2019-319850.
5 Cornelis R, Chang HD, Radbruch A. Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells[J]. Curr Opin Immunol, 2021, 71: 97-102. PMID: 34303157. DOI: 10.1016/j.coi.2021.06.012.
6 Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus[J]. Expert Opin Drug Saf, 2019, 18(12): 1133-1144. PMID: 31657965. DOI: 10.1080/14740338.2019.1685978.
7 Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth[J]. J Exp Med, 1999, 189(11): 1747-1756. PMID: 10359578. PMCID: PMC2193079. DOI: 10.1084/jem.189.11.1747.
8 Zheng C, Zhang X, Zhao Z, et al. Selective binding BAFF/APRIL by the in and outside conservative region of BCMA[J]. Protein Pept Lett, 2017, 24(6): 489-494. PMID: 28260502. DOI: 10.2174/0929866524666170301115209.
9 Shaul ME, Zlotnik A, Tidhar E, et al. Tumor-associated neutrophils drive B-cell recruitment and their differentiation to plasma cells[J]. Cancer Immunol Res, 2021, 9(7): 811-824. PMID: 33906865. DOI: 10.1158/2326-6066.CIR-20-0839.
10 Giordano D, Kuley R, Draves KE, et al. BAFF produced by neutrophils and dendritic cells is regulated differently and has distinct roles in antibody responses and protective immunity against West Nile virus[J]. J Immunol, 2020, 204(6): 1508-1520. PMID: 32034064. PMCID: PMC7357242. DOI: 10.4049/jimmunol.1901120.
11 Schuh E, Musumeci A, Thaler FS, et al. Human plasmacytoid dendritic cells display and shed B cell maturation antigen upon TLR engagement[J]. J Immunol, 2017, 198(8): 3081-3088. PMID: 28283566. DOI: 10.4049/jimmunol.1601746.
12 Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival[J]. Front Immunol, 2018, 9: 2285. PMID: 30349534. PMCID: PMC6186824. DOI: 10.3389/fimmu.2018.02285.
13 Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis[J]. Nat Rev Rheumatol, 2014, 10(6): 365-373. PMID: 24614588. DOI: 10.1038/nrrheum.2014.33.
14 Yang S, Li JY, Xu W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma[J]. Crit Rev Oncol Hematol, 2014, 91(2): 113-122. PMID: 24629840. DOI: 10.1016/j.critrevonc.2014.02.004.
15 Hu S, Wang R, Zhang M, et al. BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway[J]. Biomed Pharmacother, 2019, 114: 108796. PMID: 30921706. DOI: 10.1016/j.biopha.2019.108796.
16 Salazar-Camarena DC, Ortíz-Lazareno P, Marín-Rosales M, et al. BAFF-R and TACI expression on CD3+ T cells: interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus[J]. Cytokine, 2019, 114: 115-127. PMID: 30467093. DOI: 10.1016/j.cyto.2018.11.008.
17 Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties[J]. Cytokine Growth Factor Rev, 2008, 19(3-4): 263-276. PMID: 18514565. DOI: 10.1016/j.cytogfr.2008.04.006.
18 Wang QT, Ma YK, Huang B, et al. Effect of rhTACI-Ig fusion protein on antigen-specific T cell responses from keyhole limpet haemocyanin challenged mice[J]. Mol Immunol, 2011, 49(1-2): 380-386. PMID: 21967866. DOI: 10.1016/j.molimm.2011.09.007.
19 Wang B, Shen J. NF-κB inducing kinase regulates intestinal immunity and homeostasis[J]. Front Immunol, 2022, 13: 895636. PMID: 35833111. PMCID: PMC9271571. DOI: 10.3389/fimmu.2022.895636.
20 Zhang Y, Tao M, Chen C, et al. BAFF blockade attenuates DSS-induced chronic colitis via inhibiting NLRP3 inflammasome and NF-κB activation[J]. Front Immunol, 2022, 13: 783254. PMID: 35320937. PMCID: PMC8934862. DOI: 10.3389/fimmu.2022.783254.
21 GAO P, LIU H, HUANG H, et al. The Crohn disease-associated ATG16L1T300A polymorphism regulates inflammatory responses by modulating TLR- and NLR-mediated signaling[J]. Autophagy, 2022, 18(11): 2561-2575. PMID: 35220902. PMCID: PMC9629077. DOI: 10.1080/15548627.2022.2039991.
22 Im J, Baik JE, Lee D, et al. Bacterial lipoproteins induce BAFF production via TLR2/MyD88/JNK signaling pathways in dendritic cells[J]. Front Immunol, 2020, 11: 564699. PMID: 33123136. PMCID: PMC7566273. DOI: 10.3389/fimmu.2020.564699.
23 Jacque E, Schweighoffer E, Tybulewicz VL, et al. BAFF activation of the ERK5 MAP kinase pathway regulates B cell survival[J]. J Exp Med, 2015, 212(6): 883-892. PMID: 25987726. PMCID: PMC4451135. DOI: 10.1084/jem.20142127.
24 Fodor I, Serban O, Serban DE, et al. B cell-activating factor (BAFF) in children with inflammatory bowel disease[J]. Pediatr Res, 2021, 89(7): 1798-1803. PMID: 32937648. DOI: 10.1038/s41390-020-01155-1.
25 Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation[J]. Sci Rep, 2017, 7(1): 2669. PMID: 28572616. PMCID: PMC5453945. DOI: 10.1038/s41598-017-02835-5.
26 Itotagawa E, Tomofuji Y, Kato Y, et al. SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis[J]. Rheumatology (Oxford), 2023, 62(5): 1988-1997. PMID: 36094336. PMCID: PMC10152287. DOI: 10.1093/rheumatology/keac528.
27 Migita K, Abiru S, Maeda Y, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis[J]. Hum Immunol, 2007, 68(7): 586-591. PMID: 17584580. DOI: 10.1016/j.humimm.2007.03.010.
28 Biewenga M, Heidt S, Vergunst M, et al. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis[J]. JHEP Rep, 2022, 4(5): 100460. PMID: 35368991. PMCID: PMC8971938. DOI: 10.1016/j.jhepr.2022.100460.
29 Nascimento M, Huot-Marchand S, Gombault A, et al. B-cell activating factor secreted by neutrophils is a critical player in lung inflammation to cigarette smoke exposure[J]. Front Immunol, 2020, 11: 1622. PMID: 32849550. PMCID: PMC7405926. DOI: 10.3389/fimmu.2020.01622.
30 Cai J, Gao D, Liu D, et al. Telitacicept for autoimmune nephropathy[J]. Front Immunol, 2023, 14: 1169084. PMID: 37342346. PMCID: PMC10277628. DOI: 10.3389/fimmu.2023.1169084.
31 Dhillon S. Telitacicept: first approval[J]. Drugs, 2021, 81(14): 1671-1675. PMID: 34463932. DOI: 10.1007/s40265-021-01591-1.
32 Bag-Ozbek A, Hui-Yuen JS. Emerging B-cell therapies in systemic lupus erythematosus[J]. Ther Clin Risk Manag, 2021, 17: 39-54. PMID: 33488082. PMCID: PMC7814238. DOI: 10.2147/TCRM.S252592.
33 Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus[J]. Ther Adv Musculoskelet Dis, 2019, 11: 1759720X19874309. PMID: 31565077. PMCID: PMC6755633. DOI: 10.1177/1759720X19874309.
34 Manetta J, Bina H, Ryan P, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor[J]. J Inflamm Res, 2014, 7: 121-131. PMID: 25258549. PMCID: PMC4173659. DOI: 10.2147/JIR.S67751.
35 Riccobene TA, Miceli RC, Lincoln C, et al. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice[J]. J Nucl Med, 2003, 44(3): 422-433. PMID: 12621010.
36 Wu W, Li S, Zhang W, et al. A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma[J]. Int J Mol Sci, 2014, 15(6): 9481-9496. PMID: 24879522. PMCID: PMC4100105. DOI: 10.3390/ijms15069481.
37 McWilliams EM, Lucas CR, Chen T, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib[J]. Blood Adv, 2019, 3(3): 447-460. PMID: 30737226. PMCID: PMC6373734. DOI: 10.1182/bloodadvances.2018025684.